Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology
On Wednesday, April 14th, 2021, Pacira filed a lawsuit against the American Society of Anesthesiologists (ASA) seeking pecuniary damages and the retraction of three articles that create the false and misleading impression that EXPAREL® (bupivacaine liposome injectable suspension) is not an effective analgesic. The Complaint establishes that the ASA published articles were not only scientifically unsound, but also failed to disclose that certain authors were accepting payments from competing pharmaceutical or drug device manufacturers.
Read our Press Release.
Key Declarant Statements:
- Tom Trikalinos, MD, PhD (Brown University) Summary of Declarant Statement
- Charles Mehlman, DO, MPH (Cincinnati Children’s Hospital) Summary of Declarant Statement
- Mary DiGiorgi, MPH, PhD (Pacira BioSciences, Inc.) Summary of Declarant Statement
- Catherine Vandepitte, MD, PhD (Department of Anesthesiology, Ziekenhuis Oost-Limburg (ZOL), Genk, Belgium)
Read the Complaint.
Read the Redacted Brief in Support of a Motion for Preliminary Injunction.